A package of kratom powder can look simple: plant material, a pouch, a label and a lot number. The quality work behind a responsibly handled package is less simple. Botanical material can pass through harvesting, drying, cleaning, milling, storage, international transportation, receiving, sampling, laboratory testing, packaging and distribution before it reaches a customer.
Each transfer creates a question. Is this the botanical material the supplier says it is? Was it protected from moisture and contamination? Does the laboratory sample actually represent the lot? Does the certificate of analysis match the package? Did powder and capsules come from the same released material? Can the company trace the finished package back to its source lot?
This guide maps those questions from leaf to finished lot. It describes a practical quality-control model, not a claim that every kratom company or overseas supplier follows the same process. It also does not treat quality procedures as proof that FDA has approved kratom. FDA states that no FDA-approved kratom drug products or over-the-counter drugs containing kratom are legally marketed in the United States and continues to warn consumers about kratom-related risks.[1]
Kiody’s educational position is for adults 21 and older. Kiody does not sell concentrated 7-hydroxymitragynine products. Nothing here is medical advice, dosage advice or a promise that any product is risk-free.
The short version: a quality-controlled lot needs an unbroken story
A credible finished lot should have an evidence trail that answers at least these questions:
- Who supplied the botanical material?
- What material was ordered and received?
- How was the shipment divided into identifiable lots?
- Was the material held before approval?
- How was a representative sample selected?
- Which laboratory tested it, using which methods?
- Did the results meet written specifications?
- Who approved or rejected the lot?
- What finished powder and capsule packages used that lot?
- Can the company identify where those packages were distributed?
The goal is traceability. A company should be able to move backward from a package code to the finished packaging record, the tested bulk lot, the receiving record and the supplier. It should also be able to move forward from a bulk lot to every finished package made from it. That two-way link matters when investigating a complaint, correcting a label or identifying the scope of a recall.
“How kratom is made” is not one universal recipe
Kratom is the common name for Mitragyna speciosa, a botanical native to Southeast Asia. Commercial sellers use color and variety names such as Green Maeng Da, Red Bali or White Malay, but those marketing families do not establish a universal agricultural or processing method.
One supply chain may begin with leaves from several farms that a collector combines. Another may preserve material from a smaller source. One processor may mill dried leaf before export; another may ship a coarser material for further milling. A U.S. company may purchase finished powder, package bulk powder or fill capsules. The label alone rarely explains every step.
That is why responsible descriptions should separate verified facts from assumptions. A company can accurately say that a finished package contains pure botanical leaf powder if its formulation and records support that statement. It should not invent a farm, tree age, village, drying technique or harvest season merely because those details sound appealing.
A leaf-to-lot supply-chain map
The following stages create a useful framework:
- Source and supplier qualification
- Harvest and initial collection
- Drying and moisture protection
- Cleaning, milling and sieving
- Source-lot and production-lot formation
- Export, transport and import verification
- U.S. receiving and quarantine
- Representative sampling
- Identity, contaminant and alkaloid testing
- Quality review and lot release
- Powder packaging or pure-leaf capsule filling
- Finished-package inspection
- Distribution records, complaints and recall readiness
These stages do not prove legality or safety by themselves. They organize the evidence needed to evaluate identity, condition, testing and traceability.
Stage 1: qualifying the source and supplier
Supplier qualification should happen before a purchase becomes routine. A low price and a generic certificate are not a complete qualification program.
A buyer can review:
- the supplier’s legal business identity and physical location;
- the exact material and specifications being purchased;
- processing and sanitation information;
- lot-numbering practices;
- packaging and storage controls;
- testing history and laboratory relationships;
- prior complaints, rejected lots or recalls;
- responsiveness when documentation is questioned; and
- whether records distinguish one shipment and lot from another.
For imported foods subject to the Foreign Supplier Verification Programs rule, FDA describes a risk-based system involving hazard analysis, evaluation of supplier performance and appropriate verification activities. FDA’s examples include onsite audits, sampling and testing, and review of relevant food-safety records.[2] Whether and how a specific kratom transaction fits a particular federal category requires qualified regulatory review. A responsible seller can still use the supplier-verification concepts as a quality benchmark without representing that FDA accepts kratom as a lawful dietary supplement or conventional food ingredient.
Supplier qualification is not permanent. A supplier’s reliability can change after a facility move, ownership change, new subcontractor, abnormal laboratory trend, documentation failure or contamination event. A useful program defines when reevaluation is required instead of approving a vendor indefinitely.
Questions a buyer should be able to answer
- Does the legal supplier match the name on invoices and shipping records?
- Does the supplier control processing, or does it purchase from another processor?
- Can it identify the source and production lot for each shipment?
- Are test reports issued for the actual lot being purchased?
- Will it provide the original laboratory report rather than a retyped table?
- Does it notify customers before changing facilities, methods or specifications?
- What happens when a lot fails?
An inability to answer one question does not automatically prove misconduct. Repeated contradictions, reused reports and missing lot links are stronger warning signs.
Stage 2: harvesting and initial collection
Harvest information may matter, but it is often the least documented part of a retail product page. Leaves may be collected from cultivated trees, established plantings or other sources. Material from multiple collectors may be combined before processing.
The quality concern is not to romanticize the harvest. It is to preserve enough information to understand what entered the process. Useful records can include collection area, supplier, approximate collection dates, source-lot identifier, received weight and visual condition.
At this point, foreign material can be introduced accidentally through soil, plant debris, damaged packaging, pests, equipment or handling. A processor’s receiving and sorting procedure should therefore be more meaningful than a statement that the leaf is “hand selected.” The evidence is the record of what was checked, what was removed and how rejected material was controlled.
Color and variety names should not substitute for identity. “Green,” “red” and “white” are commercial catalog families, not complete botanical authentication results. A source may use those terms to organize material, but the finished lot still needs a verifiable identity and its own test record.
Stage 3: drying and moisture protection
Drying reduces water in freshly collected plant material and makes milling and storage more practical. The important quality questions are whether the method was controlled, whether the material was protected from contamination and whether the dried leaf remained dry during storage and transportation.
No single drying story should be presented as universal. Suppliers may use indoor, covered, screened, rack, airflow-assisted or other systems. A credible company should describe a method only when it has supplier documentation supporting that description.
Moisture control matters because damp botanical material can deteriorate, clump and support microbial growth. Drying does not guarantee that a lot is microbiologically acceptable, and a normal appearance does not replace testing. A lot may look dry while still having an unknown contamination history.
Useful controls include:
- defined drying areas and cleanable contact surfaces;
- protection from animals, standing water, dust and unrelated materials;
- records showing source lot and drying dates;
- checks for visible moisture, discoloration or objectionable odor;
- packaging that limits moisture entry after drying; and
- rejection or investigation criteria for wet or damaged material.
The customer-facing takeaway is simple: “dried leaf” describes a processing state, not a safety certification.
Stage 4: cleaning, milling and sieving
Dried leaf may be cleaned, reduced in size, milled into powder and passed through a screen or sieve. Milling changes particle size; it does not turn leaf into an extract.
This distinction is essential:
- Leaf powder remains ground botanical material.
- An extract separates or concentrates selected material from the leaf using an extraction process.
- Enhanced powder may combine leaf powder with an extract or added alkaloid material.
- Concentrated 7-OH products are not interchangeable with ordinary ground leaf.
A finer screen can affect texture and flow, but it does not prove greater purity, potency or safety. “Micronized” is also incomplete unless the seller defines what it means and has a particle-size specification.
Milling creates its own controls. Equipment must not carry material from the previous run into the next lot. The operator should know what was milled before the current material, how equipment was cleaned and how the lot was identified during processing. Magnets, screens or other physical controls may be used to reduce foreign-material risks, but their use should be documented rather than assumed.
After milling, the processor should reconcile quantities. Large unexplained differences between input and output weights deserve review. Normal losses can occur through dust collection, screening and equipment hold-up, but they should not make the lot impossible to track.
Stage 5: forming a lot without losing its history
A “lot” is a defined quantity treated as a unit for control and traceability. It is not merely a random code printed on a pouch.
A source lot may become a processing lot, which may then become one or more finished packaging lots. Conversely, a processor may combine material from several source lots into a larger blended lot. Combining material is not automatically improper, but it changes the traceability question. The finished record should identify every contributing lot and the quantity used.
Lot formation should be defined before testing. A company should not test one container and then add untested material to the lot afterward while continuing to use the same certificate. If material changes, the represented population changes.
Strong lot records include:
- unique lot identifier;
- source or parent lots;
- material name and form;
- quantity at formation;
- date and processing location;
- equipment or line used when relevant;
- sampling event and sample identifiers;
- laboratory report number;
- release, rejection or hold status; and
- every finished product made from the lot.
A color name alone is not a lot number. “Green Maeng Da” may describe many different batches over several years.
Stage 6: export, transportation and import verification
Quality controls can fail between the processing site and the receiving warehouse. Bags can be punctured, seals can break, labels can separate from containers, and moisture or pests can affect a shipment.
Receiving documentation should connect commercial records with the physical shipment. Important fields include exporter, importer, product description, source lot, container count, weight, seal information when used and dates of shipment and receipt.
FDA’s FSVP materials emphasize that supplier evaluation may consider harvesting, manufacturing, packing, sanitation, storage and transportation practices.[3] That is a useful reminder: a laboratory report is only one part of supply-chain verification.
A company should not claim “FDA approved import” merely because a shipment cleared a logistics or customs step. Admission, release or lack of detention is not FDA product approval.
Stage 7: receiving and quarantine
When bulk material reaches a U.S. facility, it should not automatically move to the packaging line. A quarantine status separates received material from approved material while records, condition and test requirements are reviewed.
The receiving check can document:
- number and condition of containers;
- seal condition;
- supplier and source-lot labels;
- visible water damage, tears, pests or contamination;
- received weight;
- purchase-order and invoice match;
- date and receiving employee; and
- assigned internal identifier and location.
FDA’s Part 111 guidance for dietary supplements describes identifying unique lots within shipments so they can be traced to the supplier, receipt date, material status and distributed product. It also describes holding materials under conditions that protect against contamination, deterioration and mix-ups.[4] Kiody uses these concepts as a quality-system benchmark. This does not mean FDA has accepted kratom as a lawful dietary supplement.
Quarantine must be real. A “hold” label has little value if anyone can move or use the material. Physical separation, system status, access control or a combination can prevent accidental release.
Stage 8: selecting a representative sample
Laboratory results describe the sample submitted. The central question is whether that sample reasonably represents the entire lot.
Powder can vary within a large container or across multiple containers. Taking a scoop from the easiest-to-reach bag may not reflect the lot. A written sampling plan should state who samples, which containers are selected, where increments are taken, how they are combined, how tools are cleaned and how the final sample is sealed and labeled.
Under 21 CFR Part 111, a representative sample is based on rational criteria, such as random sampling, and is intended to portray the material being sampled accurately.[5] The rule also describes representative samples for unique lots, shipments, in-process materials and finished batches.[6]
Useful sample records include:
- lot and container identifiers;
- date, time and location;
- sampler;
- number of containers in the lot and number sampled;
- sampling pattern;
- total sample quantity;
- sample seal or custody number;
- requested tests; and
- laboratory shipment information.
The laboratory cannot repair a weak sample. An advanced instrument can measure the submitted jar precisely while the jar still fails to represent the lot.
Stage 9: confirming botanical and product identity
Identity testing asks whether the material is what it is represented to be. It is separate from contaminant testing.
A material can have acceptable heavy-metal and microbiological results yet still be the wrong botanical. Conversely, correct Mitragyna speciosa identity does not prove the absence of Salmonella, elevated metals or added concentrated alkaloids.
Depending on material form and method suitability, identity evaluation may use macroscopic or microscopic features, chemical fingerprinting, marker compounds or other validated approaches. A generic visual inspection of brown-green powder is not highly discriminating because many powdered botanicals can look similar.
The method should fit the question and matrix. A method suitable for intact leaf may not work the same way after fine milling. A chemistry method that detects mitragynine can support identity but should not automatically be described as proving geographic origin, commercial strain name or absence of every adulterant.
Stage 10: evaluating the supplier’s certificate of analysis
A supplier certificate of analysis is useful evidence only when its identity and reliability are established.
The COA should identify:
- supplier and laboratory;
- material and lot;
- sample or report number;
- dates received, tested and reported;
- methods;
- specifications or limits;
- numerical results, not only “pass”;
- units and reporting limits;
- authorization or electronic verification; and
- amendments or report version.
For dietary-supplement components, 21 CFR 111.75 permits reliance on certain supplier COAs only after supplier qualification establishes reliability, with documentation, periodic reconfirmation and a report that includes methods, limits and actual results.[7] A strong supplier-control program borrows that discipline: it does not rely on a supplier PDF indefinitely without independent confirmation.
Warning signs include a report used for multiple unrelated lots, cropped laboratory identity, altered fonts, impossible dates, missing units, test panels inconsistent with the product and results copied into a seller-created template without the original report.
Stage 11: testing hazards and product classification
A responsible test plan is based on the material, supplier, process and intended specifications. One test does not answer every quality question.
Microbiological testing
Common panels may address Salmonella, E. coli, coliforms, aerobic organisms, yeast and mold. The specific specification and method must be defined. “Microbial tested” is too vague.
FDA-posted kratom recalls demonstrate why lot-specific microbial control matters. In October 2025, a company recalled named Monarch Premium kratom powder varieties and identified specific UPC and lot codes because of potential Salmonella contamination.[8] The lesson is not that every kratom lot is contaminated. It is that product form, package size and lot code determine the scope of an actual recall.
Heavy metals
Testing may include lead, arsenic, cadmium and mercury, with other elements added based on risk. A concentration result must include units, method and reporting limit. Concentration is not the same thing as a personalized exposure assessment.
Pesticides and mycotoxins
Panel scope matters. A statement that a lot “passed pesticides” is incomplete without the compounds tested, reporting limits and specifications. Mold counts and mycotoxin measurements are different tests; one should not be used as a substitute for the other.
Alkaloid testing and product form
Alkaloid results can help characterize mitragynine, 7-OH and other measured compounds. They also help detect whether a product represented as ordinary leaf appears inconsistent with that representation.
Results must be read with correct units and basis. Percent by weight, milligrams per gram, parts per million and milligrams per finished article are related but not interchangeable. Dry-weight and as-received results can differ.
As of August 28, 2026, the federal 7-OH threshold action proposing 0.050% by dry weight and 1 milligram per article remains a proposal, not effective federal law. The comment deadline was extended to September 10, 2026.[9] A separate federal Schedule I order for mitragynine pseudoindoxyl, MGM-15 and MGM-16 took effect August 26, 2026.[10]
Supply-chain records should therefore keep ordinary botanical leaf separate from extracts, enhanced products, concentrated 7-OH and scheduled derivatives. A seller should never use “kratom” as a single inventory description for materially different product types.
Stage 12: quality review and lot release
Testing is not release. A person with defined quality authority should compare the correct report with the correct lot and written specifications.
A release review should verify:
- lot identity and chain of custody;
- laboratory and report authenticity;
- method and matrix suitability;
- every required result and specification;
- deviations, retests or amended reports;
- supplier documentation;
- packaging or storage issues; and
- final approved, rejected or held disposition.
If a specification is not met, the lot should not be quietly renamed or blended into another lot to dilute a problem. Any investigation, resampling or retesting should follow a written procedure and preserve the original result.
Part 111 requires quality-control approval or rejection before release of repackaged or relabeled dietary-supplement batches.[11] Again, Kiody cites this as a rigorous benchmark, not as a claim that FDA approves kratom products under the dietary-supplement framework.
Stage 13: packaging botanical powder
Packaging creates a finished lot that customers can identify. The packaging record should connect the released bulk lot to every pouch size, count and label version.
Controls can include:
- verified clean line and equipment;
- correct bulk-lot staging;
- approved packaging components;
- label and version checks;
- target and actual net quantity checks;
- seal inspection;
- lot-code legibility;
- reconciliation of labels and finished units; and
- documented disposition of damaged or incorrect packages.
A product can have acceptable bulk test results and still be released incorrectly if the wrong label, lot code or quantity is used. Finished-package review is therefore not redundant.
Stage 14: filling pure-leaf capsules
Pure-leaf capsules add a manufacturing step but should not change the underlying botanical identity. If capsules contain only the released leaf powder and the disclosed shell, the record should show that clearly.
The capsule record should identify:
- released bulk leaf lot;
- capsule-shell type and lot;
- target fill weight;
- in-process weight checks;
- equipment and cleaning record;
- start and finish quantities;
- rejected units;
- finished capsule lot; and
- package counts made from that lot.
“Approximately 500 mg per capsule” describes the target fill amount, not a dose recommendation and not a statement of alkaloid content. The actual count and fill claim should be verified through production controls. A 60-count bottle of 500 mg capsules describes approximately 30 grams of leaf fill before normal manufacturing variation; it does not mean 500 mg of mitragynine or 7-OH.
Powder and capsules made from the same bulk lot may appropriately reference the same underlying bulk COA when the documentation proves the relationship. The finished capsule process still requires its own records, packaging checks and lot link.
Stage 15: finished-package inspection and reserve material
Before distribution, a representative set of finished packages should be inspected for:
- correct product name and form;
- ingredient statement;
- quantity or capsule count;
- lot code;
- seal and closure;
- label placement and readability;
- required warnings and age statement;
- QR or COA link accuracy; and
- absence of visible package damage.
FDA’s Part 111 framework describes reserve samples identified by lot and held in sufficient quantity for later testing. It also describes retention periods tied to shelf-life dating or the last distribution of the batch.[12] A reserve sample allows a company to examine the actual packaged lot if a later complaint or question arises.
A reserve sample should remain sealed, identified and stored under controlled conditions. An open jar on an office shelf is not a strong reserve-sample program.
Stage 16: distribution and recall readiness
Traceability does not end when a package leaves the building. Distribution records should show which finished lot went to which customer, retail account, fulfillment location or shipment range.
When a complaint arrives, the company should capture product name, lot, purchase date, package condition, photos, storage information and the nature of the concern. It should protect private health information and escalate urgent situations appropriately.
The system should support two rapid questions:
- Where did every package from this lot go?
- Which bulk materials and records produced this package?
If a recall becomes necessary, those answers reduce both under-inclusion and unnecessary over-inclusion. A company should not announce that “all kratom” is affected when the evidence identifies one lot, and it should not limit a recall to one package size when the same bulk lot was used in several sizes.
What customers can verify without touring a facility
Customers usually cannot inspect every supply-chain stage. They can still look for visible evidence:
- a legible lot or batch code;
- a COA that matches that code;
- product form clearly stated as leaf, capsule or extract;
- complete ingredients;
- quantity or count;
- laboratory identity and report number;
- actual numerical results and units;
- current contact information;
- intact packaging and seal; and
- a clear problem-reporting process.
Customers should be cautious when a seller claims a permanent “golden batch,” uses one COA for years, hides the product lot, promises identical effects from every batch or describes a laboratory logo as FDA approval.
Common supply-chain warning signs
- No lot code on the package
- A COA with a different lot number
- The same COA used for many years of inventory
- No original laboratory identity or report number
- “Passed everything” without test names or values
- A leaf product with unusually elevated 7-OH but no clear product-form explanation
- Supplier stories that change between pages
- Unsupported claims of exclusive farms or ancient trees
- Capsules described as pure leaf while ingredients mention extract or enhancement
- Product moved from hold to sale before results are available
- Retesting until a favorable result appears without an investigation
- No way to identify customers who received a lot
No single warning sign proves contamination or fraud. Several connected documentation failures justify closer review.
Frequently asked questions
Is all kratom powder made the same way?
No. Sources, collection, drying, milling, lot formation, testing and packaging can differ. A responsible seller should describe only verified steps.
Does grinding leaf create an extract?
No. Milling changes particle size. Extraction separates or concentrates material from the botanical.
What is the difference between a source lot and finished lot?
A source lot identifies incoming or supplier material. A finished lot identifies packaged powder or capsules. Records should link them.
Can several source lots be combined?
They can be combined under a defined process, but the finished record should identify every contributing lot. Testing must represent the combined lot rather than only one component.
Why quarantine material that already has a supplier COA?
Receiving condition, report authenticity, lot match and supplier reliability still need review. A supplier COA should not create automatic release.
Does an ISO/IEC 17025 logo prove every result is accredited?
No. The laboratory’s current scope must cover the relevant method, analyte, matrix and location. The specific report may also distinguish accredited and non-accredited results.
Can a COA prove the entire lot is safe?
No. A report describes the sample tested and the analytes requested. Its value depends on representative sampling, suitable methods, correct limits and a genuine lot match.
Why test finished capsules if the powder was tested?
Capsule filling introduces shells, equipment, handling, counts, fill-weight controls and packaging. The finished process needs its own documentation even when the parent powder COA remains relevant.
What does “500 mg capsule” mean?
It refers to approximately 500 milligrams of leaf fill per capsule when that is the verified target. It is not 500 milligrams of mitragynine, 7-OH or total alkaloids, and it is not dosage advice.
Does a low 7-OH result prove a product is ordinary leaf?
It can support the evaluation, but product classification should also consider formulation, manufacturing records, other alkaloid results and applicable law. One number should not replace the full record.
Are federal 7-OH thresholds already effective?
The proposed federal 0.050% dry-weight and 1-milligram-per-article criteria were not effective law as of August 28, 2026; the comment period runs through September 10, 2026. The separate Schedule I order for mitragynine pseudoindoxyl, MGM-15 and MGM-16 is effective.
Does Kiody sell concentrated 7-OH?
No. Kiody’s product and educational framework separates ordinary botanical leaf from extracts, enhanced products, concentrated 7-OH and synthetic or semi-synthetic derivatives.
Can quality controls make a kratom product FDA approved?
No. Quality systems and FDA approval are different concepts. FDA states that no FDA-approved kratom drugs or over-the-counter drugs containing kratom are legally marketed in the United States.[1]
Sources
- U.S. Food and Drug Administration, FDA and Kratom.
- FDA, FSMA Final Rule on Foreign Supplier Verification Programs.
- FDA, FSVP Key Requirements.
- FDA, Small Entity Compliance Guide for Dietary Supplement CGMP.
- Electronic Code of Federal Regulations, 21 CFR Part 111, Subpart A.
- Electronic Code of Federal Regulations, 21 CFR § 111.80.
- Electronic Code of Federal Regulations, 21 CFR § 111.75.
- FDA, 2025 Monarch Premium Kratom Powder Recall.
- Federal Register, 7-OH Threshold Comment-Period Extension, August 26, 2026; and DEA proposed threshold action, July 6, 2026.
- Federal Register, Temporary Schedule I Placement of Mitragynine Pseudoindoxyl, MGM-15 and MGM-16, effective August 26, 2026.
- Electronic Code of Federal Regulations, 21 CFR § 111.420.
- Electronic Code of Federal Regulations, 21 CFR § 111.83.